DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, Jadhav RR, Louie AD, Lin CL, Kroczak T, Chen Y, Jin VX, Abboud-Werner SL, Leach RJ, Hernandez J, Thompson IM, Saranchuk J, Drachenberg D, Chen CL, Mai S, Huang TH.
Horning AM, et al. Among authors: huang th.
Prostate. 2015 Nov;75(15):1790-801. doi: 10.1002/pros.23052. Epub 2015 Sep 1.
Prostate. 2015.
PMID: 26332453